Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Regulation of the cytotoxic effect of human ‘normal killer cells’ on tumor cell lines by neuraminidase-treated T-lymphocytes

Summary

Subpopulations of peripheral blood lymhocytes (PBL) from healthy individuals were separated according to their capacity to form various rosettes and tested for their cytotoxic activity on cell lines of urinary bladder and breast carcinomas. The subpopulation exerting the highest natural cytotoxic activity was characterized by the presence of cell surface Fc-receptors and by the lack of receptors for sheep red blood cells and for C'3 on their surface. Treatment with vibrio cholera neuraminidase (VCN) increased the cytotoxicity of unseparated PBL to a level twice as high as that of untreated PBL. The attachment of T-lymphocytes to tumor monolayers was increased several fold after VCN-treatment, while the attachment of other lymphocyte subpopulations was not. Evidence is presented that the augmentation of the cytotoxicity of PBL following VCN-treatment results from the interaction of VCN-treated T-lymphocytes, attached to target cells, with normal killer cells. It is suggested that augmentation of the activity of killer cells by T-lymphocytes may play a role in antitumor defense mechanisms.

This is a preview of subscription content, log in to check access.

Abbreviations

CMC:

Cell-mediated cytolysis

E-rosettes:

Rosettes formed with sheep red blood cells

EA-rosettes:

Rosettes formed with red blood cells coated with antibody

EAC'-rosettes:

Rosettes formed with red blood cells coated with antibody and complement

FCS:

Heat inactivated fetal calf serum

PBL:

Peripheral blood lymphocytes

RBC:

Red blood cells

RF-TAL:

E-rosette forming, target-attached lymphocytes

SRBC:

Sheep red blood cells

VCN:

Vibrio cholera neuraminidase

References

  1. 1.

    Bakács, T., Gergely, P., Cornain, S., Klein, E.: Characterization of human lymphocyte subpopulations for cytotoxicity against tumor-derived monolayer cultures. Int. J. Cancer 19, 441 (1977)

  2. 2.

    Becker, S., Fenyö, E. A., Klein, E.: The “natural killer” cell in the mouse does not require H-2 homology and is not directed against type or group-specific antigens of murine C viral proteins. Europ. J. Immunol. 6, 882 (1976)

  3. 3.

    Bekesi, J. G., Roboz, J. P., Walter, L., Holland, J. F.: Stimulation of specific immunity against cancer by neuraminidase treated tumor cells. Behring Inst. Mitt. 55, 309 (1974)

  4. 4.

    Bubenik, J., Barešová, M., Viklicky, V., Jakoubková, I., Saincrova, H., Donner, J.: Established cell line of urinary bladder carcinoma (T24) containing tumor specific antigen. Int. J. Cancer 11, 765 (1973)

  5. 5.

    Boyum, A.: Isolation of mononuclear cells and granulocytes from human blood. Scand. J. clin. Lab. Invest. 97, 77 (1968)

  6. 6.

    Cailleau, R., Young, R., Olive, M., Reeves, W. J., Jr.: Breast tumor cell lines from pleural effusions. J. nat. Cancer Inst. 53, 661 (1974)

  7. 7.

    De Vries, J. E., Carmain, Santoso, Runke, P.: Cytotoxicity of non-T versus T-lymphocytes from melanoma patients and healthy donors on short and long-term cultured melanoma cells. Int. J. Cancer 14, 427 (1974)

  8. 8.

    Galili, U., Schlesinger, M.: The formation of stable E-rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or of sheep red blood cells. J. Immunol. 112, 1628 (1974)

  9. 9.

    Galili, U., Schlesinger, M.: Studies on the formation of E-rosettes by human T-lymphocytes and thymus cells. The effect of temperature metabolic inhibitors and anti T-sera. Israel J. med. Sci. 11, 1357 (1975)

  10. 10.

    Galili, U., Klein, E., Schlesinger, M.: Human T-lymphocyte receptors for sheep red blood cells and specific antigens: Are they identical sites on the cell membrane? J. Immunol. 119, 104 (1977)

  11. 11.

    Galili, U., Caine, M., Servadio, C., Schlesinger, M.: Specific attachment of T-lymphocytes from cancer patients to tumor cells. Cancer Letters 3, 121 (1977)

  12. 12.

    Herberman, R. B., Nunn, M. E., Holden, H. T., Lavrin, D. M.: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 16, 230 (1975)

  13. 13.

    Herberman, R. B., Oldham, R. K.: Problems associated with study of cell-mediated immunity to human tumors by microcytotoxicity assays. J. nat. Cancer Inst. 55, 749 (1975)

  14. 14.

    Hersey, P., Edwards, A., Edwards, J., Adams, E., Milton, J. W., Nelson, D. S.: Specificity of cell mediated cytotoxicity against human melanoma lines: Evidence for “non-specific” killing by activated T-cells. Int. J. Cancer 16, 173 (1975)

  15. 15.

    Kedar, E., de Landazuri, M. O., Fahey, J. L.: Enzymatic enhancement of cell mediated cytotoxicity and antibody-dependent cell cytotoxicity. J. Immunol. 112, 26 (1974)

  16. 16.

    Kiessling, R., Klein, E., Wigzell, H.: “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Europ. J. Immunol. 5, 112 (1975)

  17. 17.

    Kiuchi, M., Takasugi, M.: The non-selective cytotoxic cell (N-cell). J. nat. Cancer Inst. 56, 575 (1976)

  18. 18.

    North, R. J., Kirstein, D. P.: T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of non-specific immunity to unrelated tumor and bacterial parasites. J. exp. Med. 145, 275 (1977)

  19. 19.

    Peter, H. H., Pavie-Ficher, J., Friedman, W. H., Aubert, C., Cesarini, J. P., Roubin, R., Kourilsky, F. M.: Cell-mediated cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (IGR3). J. Immunol. 115, 539 (1975)

  20. 20.

    Pross, H. F., Jondal, M.: Cytotoxic lymphocytes from normal donors a functional marker of human non-T lymphocytes. Clin. exp. Immunol. 21, 226 (1975)

  21. 21.

    Sanford, B. H.: An alteration in tumor histocompatibility induced by neuraminidase. Transplantation 5, 1273 (1967)

  22. 22.

    Sedlacek, H. H., Seiler, F. R.: Dose dependency of the effect of syngeneic Vibrio-Cholera-Neuraminidase-treated mastocytoma cells on the life span of DBA f/2 mice. Behring Inst. Mitt. 55, 343 (1974)

  23. 23.

    Takasugi, M., Klein, E.: A microassay for cell-mediated immunity. Transplantation 9, 219 (1970)

  24. 24.

    Takasugi, M., Mickey, M. R., Terasaki, P. I.: Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res. 33, 2898 (1973)

  25. 25.

    Takasugi, M., Mickey, M. R., Terasaki, P. I.: Studies on specificity of cell-mediated immunity to human tumors. J. nat. Cancer Inst. 53, 1527 (1974)

  26. 26.

    Watkins, E., Gray, B. N., Anderson, L. L., Baralt, O. L., Nebril, L. R., Waters, M. F., Connery, C. K.: Neuraminidase-mediated augmentation of in vitro immune response of patients with solid tumors. Int. J. Cancer 14, 799 (1974)

  27. 27.

    Weiss, L., Cudney, T. L.: Some effects of neuraminidase on the in vitro interactions between spleen and mastocytoma (P815) cells. Int. J. Cancer 7, 187 (1971)

  28. 28.

    Wekerle, H., Lonai, P., Feldman, M.: Fractionation of antigen reactive cells on a cellular immunoadsorbant: Factors determining recognition of antigens by T-lymphocytes. Proc. nat. Acad. Sci. (Wash.) 69, 1620 (1972)

Download references

Author information

Correspondence to Michael Schlesinger.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Galili, U., Schlesinger, M. Regulation of the cytotoxic effect of human ‘normal killer cells’ on tumor cell lines by neuraminidase-treated T-lymphocytes. Cancer Immunol Immunother 4, 33–39 (1978). https://doi.org/10.1007/BF00205568

Download citation

Keywords

  • Carcinoma
  • Tumor Cell
  • Blood Cell
  • Cell Surface
  • Target Cell